Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -3.78% Earnings Yield (Joel Greenblatt) % is -4.35% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 1,011 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 78.34% on this metric.
CTT Pharmaceutical Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was $3.54 Mil.
CTT Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil. CTT Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -4.35%.
The historical rank and industry rank for CTT Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CTTH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.29 Med: 0 Max: 0
Current: -4.28
CTTH's Earnings Yield (Joel Greenblatt) % is ranked worse than 78.34% of 1011
companies
in the Drug Manufacturers industry
Industry Median: 3.34
vs CTTH: -4.28
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. CTT Pharmaceutical Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
CTT Pharmaceutical Holdings Earnings Yield (Joel Greenblatt) % Related Terms
CTT Pharmaceutical Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for CTT Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
CTT Pharmaceutical Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -4.35% mean?
CTT Pharmaceutical Holdings (CTTH) has a Earnings Yield (Joel Greenblatt) % of -4.35% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on CTT Pharmaceutical Holdings and its competitors. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #792 out of 1011 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is CTT Pharmaceutical Holdings' Earnings Yield (Joel Greenblatt) % too high?
CTT Pharmaceutical Holdings' current Earnings Yield (Joel Greenblatt) % is -4.35%. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #792 out of 1011 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CTT Pharmaceutical Holdings' Earnings Yield (Joel Greenblatt) % compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #792 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.34, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current Earnings Yield (Joel Greenblatt) % is -4.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Earnings Yield (Joel Greenblatt) % of -4.35%. The current Earnings Yield (Joel Greenblatt) % is -4.35%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Earnings Yield (Joel Greenblatt) % is -4.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
